Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 5 February 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 3MB, 220 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 48 results:
Author Title [ Type(Desc)] Year
Filters: Author is Yin, H.  [Clear All Filters]
Journal Article
F. Lapi, Azoulay, L., Niazi, M. T., Yin, H., Benayoun, S., and Suissa, S., “Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer”, Jama, vol. 310, pp. 289-96, 2013.
A. J. Klil-Drori, Tascilar, K., Yin, H., Aprikian, A., Bitton, A., and Azoulay, L., “Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate Cancer”, Am J Epidemiol, vol. 184, pp. 15-22, 2016.
B. M. Hicks, Klil-Drori, A. J., Yin, H., Campeau, L., and Azoulay, L., “Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer”, Epidemiology, vol. 28, pp. 712-718, 2017.
J. Assayag, Yin, H., Benayoun, S., Pollak, M. N., Suissa, S., and Azoulay, L., “Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer”, Cancer Causes Control, vol. 24, pp. 839-45, 2013.
F. Khosrow-Khavar, Rej, S., Yin, H., Aprikian, A., and Azoulay, L., “Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer”, J Clin Oncol, vol. 35, pp. 201-207, 2017.
A. J. Klil-Drori, Santella, C., Tascilar, K., Yin, H., Aprikian, A., and Azoulay, L., “Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study”, Drug Saf, 2019.
A. J. Klil-Drori, Yin, H., Tagalakis, V., Aprikian, A., and Azoulay, L., “Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism”, Eur Urol, vol. 70, pp. 56-61, 2016.
B. M. Hicks, Yin, H., Bladou, F., Ernst, P., and Azoulay, L., “Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia”, Thorax, vol. 72, pp. 596-597, 2017.
L. Azoulay, Yin, H., Benayoun, S., Renoux, C., Boivin, J. F., and Suissa, S., “Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer”, Eur Urol, vol. 60, pp. 1244-50, 2011.
B. M. Hicks, Filion, K. B., Yin, H., Sakr, L., Udell, J. A., and Azoulay, L., “Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study”, Bmj, vol. 363, p. k4209, 2018.
F. Khosrow-Khavar, Yin, H., Barkun, A., Bouganim, N., and Azoulay, L., “Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer”, Ann Oncol, vol. 29, pp. 744-748, 2018.
D. Abrahami, Renoux, C., Yin, H., Fournier, J. P., and Azoulay, L., “The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation”, Thromb Haemost, 2020.
J. L. Faillie, Yu, O. H., Yin, H., Hillaire-Buys, D., Barkun, A., and Azoulay, L., “Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus”, JAMA Intern Med, vol. 176, pp. 1474-1481, 2016.
O. H. Yu, Yin, H., and Azoulay, L., “The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death”, Can J Diabetes, vol. 39, pp. 383-9, 2015.
F. Lapi, Azoulay, L., Yin, H., Nessim, S. J., and Suissa, S., “Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study”, Bmj, vol. 346, p. e8525, 2013.
D. Abrahami, Douros, A., Yin, H., Yu, O. H. Y., Renoux, C., Bitton, A., and Azoulay, L., “Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study”, Bmj, vol. 360, p. k872, 2018.
A. Douros, Rouette, J., Yin, H., Yu, O. H. Y., Filion, K. B., and Azoulay, L., “Dipeptidyl Peptidase-4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes”, Diabetes Care, 2019.
A. Douros, Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., and Azoulay, L., “Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy”, Diabetes Care, vol. 41, pp. 2330-2338, 2018.
B. M. Hicks, Yin, H., Yu, O. H., Pollak, M. N., Platt, R. W., and Azoulay, L., “Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink”, Bmj, vol. 355, p. i5340, 2016.
I. Matok, Azoulay, L., Yin, H., and Suissa, S., “Immortal time bias in observational studies of drug effects in pregnancy”, Birth Defects Res A Clin Mol Teratol, vol. 100, pp. 658-62, 2014.
D. Abrahami, Douros, A., Yin, H., Yu, O. H., Faillie, J. L., Montastruc, F., Platt, R. W., Bouganim, N., and Azoulay, L., “Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study”, Bmj, vol. 363, p. k4880, 2018.
J. Rouette, Yin, H., Yu, O. H. Y., Bouganim, N., Platt, R. W., and Azoulay, L., “Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes”, Diabet Med, 2020.
D. Abrahami, Yin, H., Yu, O. H. Y., Pollak, M. N., and Azoulay, L., “Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes”, Epidemiology, vol. 29, pp. 246-253, 2018.
L. Azoulay, Assimes, T. L., Yin, H., Bartels, D. B., Schiffrin, E. L., and Suissa, S., “Long-term use of angiotensin receptor blockers and the risk of cancer”, PLoS One, vol. 7, p. e50893, 2012.
J. P. Fournier, Yin, H., Yu, O. H., and Azoulay, L., “Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus”, Cmaj, vol. 186, pp. 1138-45, 2014.
B. M. Hicks, Yin, H., Sinyavskaya, L., Suissa, S., Azoulay, L., and Brassard, P., “Metformin and the incidence of viral associated cancers in patients with type 2 diabetes”, Int J Cancer, vol. 141, pp. 121-128, 2017.
A. Douros, Yin, H., Yu, O. H. Y., Filion, K. B., Azoulay, L., and Suissa, S., “Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events”, Diabetes Care, vol. 40, pp. 1506-1513, 2017.
Y. Lian, Yin, H., Pollak, M. N., Carrier, S., Platt, R. W., Suissa, S., and Azoulay, L., “Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer”, Eur Urol, vol. 70, pp. 808-815, 2016.
M. Tuccori, Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., and Azoulay, L., “Pioglitazone use and risk of bladder cancer: population based cohort study”, Bmj, vol. 352, p. i1541, 2016.
A. J. Klil-Drori, Yin, H., Abenhaim, H. A., Fort, G. G. du, and Azoulay, L., “Prolactin-Elevating Antipsychotics and the Risk of Endometrial Cancer”, J Clin Psychiatry, vol. 78, pp. 714-719, 2017.
D. Abrahami, Douros, A., Yin, H., Yu, O. H. Y., and Azoulay, L., “Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes”, Diabetes Care, vol. 42, pp. e150-e152, 2019.
O. Yu, Azoulay, L., Yin, H., Filion, K. B., and Suissa, S., “Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia”, Am J Med, vol. 131, pp. 317.e11-317.e22, 2018.
K. B. Filion, Douros, A., Azoulay, L., Yin, H., Yu, O. H., and Suissa, S., “Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study”, Br J Clin Pharmacol, 2019.
C. Santella, Renoux, C., Yin, H., Yu, O. H. Y., and Azoulay, L., “Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men with Late-Onset Hypogonadism”, Am J Epidemiol, 2019.
J. P. Fournier, Yin, H., Nessim, S. J., Montastruc, J. L., and Azoulay, L., “Tramadol for noncancer pain and the risk of hyponatremia”, Am J Med, vol. 128, pp. 418-25.e5, 2015.
J. P. Fournier, Azoulay, L., Yin, H., Montastruc, J. L., and Suissa, S., “Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain”, JAMA Intern Med, vol. 175, pp. 186-93, 2015.
L. Bensimon, Yin, H., Suissa, S., Pollak, M. N., and Azoulay, L., “Type 2 diabetes and the risk of mortality among patients with prostate cancer”, Cancer Causes Control, vol. 25, pp. 329-38, 2014.
L. Azoulay, Yin, H., Renoux, C., and Suissa, S., “The use of atypical antipsychotics and the risk of breast cancer”, Breast Cancer Res Treat, vol. 129, pp. 541-8, 2011.
L. Azoulay, Soldera, S., Yin, H., and Bouganim, N., “Use of Calcium Channel Blockers and Risk of Breast Cancer: A Population-based Cohort Study”, Epidemiology, vol. 27, pp. 594-601, 2016.
A. Douros, Abrahami, D., Yin, H., Yu, O. H. Y., Renoux, C., Hudson, M., and Azoulay, L., “Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes”, Epidemiology, vol. 29, pp. 904-912, 2018.
V. Mandilaras, Bouganim, N., Yin, H., Asselah, J., and Azoulay, L., “The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer”, Br J Cancer, vol. 116, pp. 103-108, 2017.
M. Tuccori, Wu, J. W., Yin, H., Majdan, A., and Azoulay, L., “The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes”, Diabetes Care, vol. 38, pp. 2083-9, 2015.
J. Rouette, Yin, H., Pottegard, A., Nirantharakumar, K., and Azoulay, L., “Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer”, Drug Saf, 2020.
R. Pradhan, Yin, H., Yu, O. H. Y., and Azoulay, L., “The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study”, Drug Saf, 2019.
B. Smiechowski, Azoulay, L., Yin, H., Pollak, M. N., and Suissa, S., “The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus”, Cancer Epidemiol Biomarkers Prev, vol. 22, pp. 1877-83, 2013.
B. B. Smiechowski, Azoulay, L., Yin, H., Pollak, M. N., and Suissa, S., “The use of metformin and the incidence of lung cancer in patients with type 2 diabetes”, Diabetes Care, vol. 36, pp. 124-9, 2013.
L. Azoulay, Yin, H., Filion, K. B., Assayag, J., Majdan, A., Pollak, M. N., and Suissa, S., “The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study”, Bmj, vol. 344, p. e3645, 2012.
C. Santella, Yin, H., Hicks, B. M., Yu, O. H. Y., Bouganim, N., and Azoulay, L., “Weight-lowering effects of glucagon-like peptide-1 receptor agonists and detection of breast cancer among obese women with diabetes”, Epidemiology, 2020.
[Page last reviewed 4 February 2021]